Amgen completes acquisition of Mustafa Nevzat Pharmaceuticals
12 June 2012 | By Amgen
Amgen announced the completion of the acquisition of more than 99 percent of the shares of Mustafa Nevzat Pharmaceuticals...
List view / Grid view
News
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
12 June 2012 | By Sanofi
Genzyme is developing LEMTRADA in MS in collaboration with Bayer HealthCare...
New epidemiological data provide additional safety evidence for Lantus®
11 June 2012 | By Sanofi
New results of a large-scale epidemiological program announced...
Stiefel signs worldwide acquisition and license agreement for Toctino®
11 June 2012 | By GlaxoSmithKline
Stiefel has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd...
Catalent expert conducts workshop on Solid Dosage Forms
11 June 2012 | By Catalent Pharma Solutions
Michael Valazza, to conduct a workshop on “Coordination of Activities and Responsibilities for Solid Dosage Forms”...
Daiichi Sankyo launches antihypertensive agent olmesartan in Mexico
11 June 2012 | By Daiichi Sankyo
Daiichi Sankyo Group’s leading antihypertensive franchise olmesartan medoxomil launched...
Sanofi submits application for regulatory approval for Lyxumia®
11 June 2012 | By Sanofi
Sanofi announced that the marketing authorization application for Lyxumia®...
A new study with ‘real world’ data shows greater efficacy of Victoza(R)
11 June 2012 | By Novo Nordisk
New data show that Victoza® provided greater reductions in HbA1c...
Lilly and Incyte’s oral JAK1 and JAK2 inhibitor, Baricitinib, showed positive results in Phase IIb study
Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA).
FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer
11 June 2012 | By Roche
Roche announced that the U.S. FDA has approved PerjetaTM (pertuzumab)...
Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
11 June 2012 | By Novartis
New long-term data for Gilenya®...
Lilly and Boehringer Ingelheim present data at the 72nd American Diabetes Association Scientific Sessions® from Phase II studies comparing investigational novel basal insulin to insulin glargine
11 June 2012 | By Boehringer Ingelheim
Eli Lilly and Company and Boehringer Ingelheim announced results from two Phase II studies...
GSK announces new 52-week data from phase III study of once-weekly albiglutide in type 2 diabetes
9 June 2012 | By GlaxoSmithKline
Detailed 52 and 32-week data from the first two Phase III studies...
New data show investigational compound dapagliflozin demonstrated significant reductions in blood sugar levels when added to sitagliptin in adults with type 2 diabetes at 24 weeks, with results maintained over 48 weeks
9 June 2012 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced results from a Phase 3 clinical study...
GSK extends tender offer for all outstanding shares of Human Genome Sciences
8 June 2012 | By GlaxoSmithKline
GSK has extended its tender offer to acquire all of the outstanding shares of HGS...
